The estimated Net Worth of Diane C. Young is at least $2.97 Milhão dollars as of 11 June 2024. Dr Young owns over 15,000 units of Celldex Therapeutics stock worth over $712,669 and over the last 9 years he sold CLDX stock worth over $1,620,670. In addition, he makes $635,997 as Sr. VP & Chief Medical Officer at Celldex Therapeutics.
Dr has made over 7 trades of the Celldex Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of CLDX stock worth $40,650 on 11 June 2024.
The largest trade he's ever made was exercising 64,000 units of Celldex Therapeutics stock on 17 August 2022 worth over $319,360. On average, Dr trades about 7,404 units every 155 days since 2015. As of 11 June 2024 he still owns at least 17,115 units of Celldex Therapeutics stock.
You can see the complete history of Dr Young stock trades at the bottom of the page.
Dr. Diane C. Young M.D. is the Sr. VP & Chief Medical Officer at Celldex Therapeutics.
As the Sr. VP & Chief Medical Officer of Celldex Therapeutics, the total compensation of Dr D at Celldex Therapeutics is $635,997. There are 5 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
Dr D is 64, he's been the Sr. VP & Chief Medical Officer of Celldex Therapeutics since . There are 7 older and 14 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Diane's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, eInc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: